Detalhe da pesquisa
1.
PRMT5 supports multiple oncogenic pathways in mantle cell lymphoma.
Blood
; 142(10): 887-902, 2023 09 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37267517
2.
Discovery of 1'-(1-phenylcyclopropane-carbonyl)-3H-spiro[isobenzofuran-1,3'-pyrrolidin]-3-one as a novel steroid mimetic scaffold for the potent and tissue-specific inhibition of 11ß-HSD1 using a scaffold-hopping approach.
Bioorg Med Chem Lett
; 69: 128782, 2022 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35537608
3.
Oral arsenic trioxide ORH-2014 pharmacokinetic and safety profile in patients with advanced hematologic disorders.
Haematologica
; 105(6): 1567-1574, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31558670
4.
INCB040093 Is a Novel PI3Kδ Inhibitor for the Treatment of B Cell Lymphoid Malignancies.
J Pharmacol Exp Ther
; 364(1): 120-130, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29127109
5.
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.
N Engl J Med
; 366(9): 799-807, 2012 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22375971
6.
Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I.
Haematologica
; 100(4): 479-88, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25616577
7.
Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer.
Cancer Cell
; 10(1): 39-50, 2006 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-16843264
8.
Resistance to PRMT5-targeted therapy in mantle cell lymphoma.
Blood Adv
; 8(1): 150-163, 2024 01 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37782774
9.
The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis.
Br J Haematol
; 161(4): 508-16, 2013 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-23480528
10.
Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.
N Engl J Med
; 363(12): 1117-27, 2010 Sep 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-20843246
11.
Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I.
Haematologica
; 98(12): 1865-71, 2013 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-24038026
12.
PRMT5 inhibition drives therapeutic vulnerability to combination treatment with BCL-2 inhibition in mantle cell lymphoma.
Blood Adv
; 7(20): 6211-6224, 2023 Oct 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-37327122
13.
Dysregulation of PRMT5 in chronic lymphocytic leukemia promotes progression with high risk of Richter's transformation.
Nat Commun
; 14(1): 97, 2023 01 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36609611
14.
Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms.
Blood
; 115(15): 3109-17, 2010 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-20130243
15.
Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis.
Blood
; 115(14): 2919-27, 2010 Apr 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-20154217
16.
Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050.
J Immunol
; 184(9): 5298-307, 2010 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-20363976
17.
Targeting OXPHOS de novo purine synthesis as the nexus of FLT3 inhibitor-mediated synergistic antileukemic actions.
Sci Adv
; 8(37): eabp9005, 2022 Sep 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-36112677
18.
Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial.
Cancer
; 117(21): 4869-4877, 2011 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-21480207
19.
Identification and characterization of INCB9471, an allosteric noncompetitive small-molecule antagonist of C-C chemokine receptor 5 with potent inhibitory activity against monocyte migration and HIV-1 infection.
J Pharmacol Exp Ther
; 338(1): 228-39, 2011 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-21459966
20.
Discovery of INCB10820/PF-4178903, a potent, selective, and orally bioavailable dual CCR2 and CCR5 antagonist.
Bioorg Med Chem Lett
; 21(5): 1442-6, 2011 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-21295478